Clinical trials: MAB
Cervical Cancer
A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer
The purpose of this study is to assess the efficacy and safety of HLX10(Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection) plus chemotherapy compared to the efficacy and safety of placebo plus chemotherapy in the…
- Trial name
- NCT04806945
- Testing
- HLX10, Paclitaxel, Cisplatin
- Where
- China
- Sponsor
- Shanghai Henlius Biotech
COVID-19
A Phase 1 Study of Human Monoclonal Antibodies, BRII-196 and BRII-198
This is a phase 1 study in which healthy adult volunteers will receive BRII-196/BRII-198 or placebo and will be assessed for safety, tolerability, and pharmacokinetics.
- Trial name
- NCT04691180
- Testing
- BRII-196 and BRII-198
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Brii Biosciences Limited
Chronic Rhinosinusitis With Nasal Polyps
A Study to Evaluate the Efficacy and Safety of MG-K10 in Adults With Chronic Rhinosinusitis With Nasal Polyps
This study aims to evaluate the efficacy and safety of MG-K10 humanized monoclonal antibody injection in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP).
- Trial name
- NCT07903194
- Testing
- MG-K10, Mometasone Furoate Nasal Spray
- Volunteers
- 210 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Hyperlipidemia
LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2
The primary objective was to evaluate the effect of 12 weeks of evolocumab administered subcutaneously every 2 weeks (Q2W) and monthly (QM) when used in combination with a statin, compared with placebo, on percent change from…
- Trial name
- LAPLACE-2 (NCT01763866)
- Testing
- Evolocumab, Ezetimibe, Atorvastatin
- Where
- 244 sites in United States, Australia and 19 more
- Volunteers
- 2,067 people
- Sponsor
- Amgen
Atopic Dermatitis
Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis)
The purpose of this study is to determine the efficacy and safety of a monoclonal antibody, OpSCF, in the treatment of adults with moderate to severe Atopic Dermatitis (Eczema). OpSCF will be compared to a placebo.
- Trial name
- NCT06101823
- Testing
- OpSCF
- Where
- 22 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Insmed Incorporated
Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease
Alzheimer's Tau Platform: Regimen A - AADvac1
The Alzheimer's Tau Platform (ATP) is a multi-center platform trial to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with donanemab, in adults aged 50-80 with late preclinical or early…
- Conditions
- Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease
- Trial name
- ATP (NCT07167966)
- Testing
- AADvac1, Donanemab
- Where
- 7 sites in United States
- Volunteers
- 450 people
- Sponsor
- Paul S. Aisen
Lymphoepithelioma-Like Carcinoma
PD-1 Monoclonal Antibody in Pre-treated Lymphoepithelioma-like Carcinoma
Lymphoepithelioma-like carcinoma (LELC) may benefit from immunocheckpoint inhibitor therapy. Although target antibody drugs for PD-1 and PD-L1 have achieved good results in immunotherapy of many malignant tumors, there is still a…
- Trial name
- NCT04430166
- Testing
- PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
Relapsed Refractory Multiple Myeloma (RRMM)
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
This study is researching a drug called REGN17372 used with another drug called linvoseltamab (each individually called "study drug" or "study drugs" when combined) in participants with relapsed (when a tumor comes back) or…
- Trial name
- NCT07455851
- Testing
- Linvoseltamab, REGN17372+Linvoseltamab
- Where
- 8 sites in Australia, Greece
- Volunteers
- 150 people
- Sponsor
- Regeneron Pharmaceuticals
Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation
A Study Evaluating the Efficacy and Safety of Neihulizumab vs "Conventional Treatment" to Treat Sr-aGvHD
This study is to assess the efficacy of Neihulizumab versus "conventional therapy" and to evaluate safety, pharmacokinetics and immunogenicity in treating steroid-refractory acute Graft-vs-Host Disease
- Trial name
- NCT02694770
- Testing
- Neihulizumab Treatment, Conventional Treatment
- Where
- 2 sites in United States
- Sponsor
- AbGenomics B.V Taiwan Branch
Advanced Solid Tumor
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in participants with advanced…
- Trial name
- NCT06241456
- Testing
- FT825, Fludarabine, Cyclophosphamide
- Where
- 14 sites in United States
- Volunteers
- 351 people
- Sponsor
- Fate Therapeutics
Allergic Rhinitis, Seasonal
A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis
Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals.
- Trial name
- NCT07154342
- Testing
- GR1802 injection
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Metastatic NUT Carcinoma, Unresectable NUT Carcinoma
Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma
This phase II trial studies how well cemiplimab works in treating patients with nuclear protein of testis (NUT) carcinoma for which no treatment is currently available (incurable) and that has spread from where it first started…
- Trial name
- NCT07050186
- Testing
- Biopsy Procedure, Biospecimen Collection, Cemiplimab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northwestern University
Ovarian Cancer
A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer.
This is an open-label, multicenter, dose-escalation study designed to assess the safety, tolerability, and pharmacokinetics of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in combination with Chemotherapy in…
- Trial name
- NCT03763123
- Testing
- Sevacizumab, Paclitaxel, Topotecan
- Where
- 6 sites in China
- Volunteers
- 48 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Acute Gout
Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients
This 8-week study is designed to determine the target dose of canakinumab (ACZ885) for the management of acute flare in gout patients who are contraindicated to Non-Steroidal anti-inflammatory drugs and/or colchicine.
- Trial name
- NCT00798369
- Testing
- Canakinumab, Triamcinolone acetonide
- Where
- 75 sites in United States, Argentina and 9 more
- Volunteers
- 200 people
- Sponsor
- Novartis
Solid Tumor, Gastric Cancer
Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors
This is an open, two-stage, phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AB011 injection in patients with CLDN18.2-positive advanced solid tumors.
- Conditions
- Solid Tumor, Gastric Cancer, Pancreatic Adenocarcinoma
- Trial name
- NCT04400383
- Testing
- AB011 Injection
- Where
- 12 sites in China
- Volunteers
- 62 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Breast Cancer
Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ®
This is a single center, randomized, blind, parallel controlled clinical trial. The primary objective is to evaluate the single dose pharmacokinetics of recombinant Humanized anti-HER-2 monoclonal antibody injection GB221 in…
- Trial name
- NCT04905667
- Testing
- GB221, Herceptin
- Where
- China
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Genor Biopharma Co., Ltd.
Breast Cancer
Molecular Triaging of Newly Diagnosed Breast Cancer
The goal of this clinical research study is to learn if using "gene signatures" can be an effective way to decide the best treatment for breast cancer patients.
- Trial name
- NCT01159236
- Testing
- Paclitaxel, Fluorouracil, Doxorubicin
- Sponsor
- M.D. Anderson Cancer Center
T-cell Type Acute Leukemia-Precursor, T-lymphoblastic Lymphoma/Leukaemia
Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia
Primary Objective: To evaluate the efficacy of isatuximab. Secondary Objectives: To evaluate the safety profile of isatuximab. To evaluate the duration of response (DOR).
- Trial name
- ISLAY (NCT02999633)
- Testing
- Isatuximab SAR650984, dexamethasone, acetaminophen
- Where
- 17 sites in United States, Finland and 5 more
- Volunteers
- 14 people
- Sponsor
- Sanofi
Multiple Myeloma, Hypogammaglobulinemia
Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
The main purpose of this study is to see if IgPro20 can prevent infection in people with multiple myeloma (MM) who have hypogammaglobulinemia from receiving bispecific monoclonal antibodies (BsAbs).
- Conditions
- Multiple Myeloma, Hypogammaglobulinemia, Hypogammaglobulinemia, Acquired
- Trial name
- NCT06976476
- Testing
- IgPro20
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer Non-Small Cell Cancer (NSCLC), EGFR Activating Mutation
EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC
This study is an open-label, multicenter, single-arm clinical study.
- Conditions
- Lung Cancer Non-Small Cell Cancer (NSCLC), EGFR Activating Mutation, PD-1 Antibody
- Trial name
- NCT07637448
- Testing
- EGFR-TKIs Combined with PD-1 Monoclonal Antibody
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Nanfang Hospital, Southern Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.